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Abstract: Doxorubicin (Dox) clinical use is limited by dose-related cardiomyopathy, becoming
more prevalent with increasing cumulative doses. Previously, we developed Dox-loaded lipid-core
nanocapsules (Dox-LNC) and, in this study, we hypothesized that self-assembling and interfacial
reactions could be used to obtain arginylglycylaspartic acid (RGD)-surface-functionalized-Dox-LNC,
which could target tumoral cells overexpressing αvβ3 integrin. Human breast adenocarcinoma
cell line (MCF-7) and human glioblastoma astrocytoma (U87MG) expressing different levels of
αvβ3 integrin were studied. RGD-functionalized Dox-LNC were prepared with Dox at 100 and
500 mg·mL−1 (RGD-MCMN (Dox100) and RGD-MCMN (Dox500)). Blank formulation (RGD-MCMN)
had z-average diameter of 162 ± 6 nm, polydispersity index of 0.11 ± 0.04, zeta potential of
+13.2 ± 1.9 mV and (6.2± 1.1)× 1011 particles mL−1, while RGD-MCMN (Dox100) and RGD-MCMN
(Dox500) showed respectively 146 ± 20 and 215 ± 25 nm, 0.10 ± 0.01 and 0.09 ± 0.03, +13.8 ± 2.3 and
+16.4 ± 1.5 mV and (6.9 ± 0.6) × 1011 and (6.1 ± 1.0) × 1011 particles mL−1. RGD complexation was
7.73 × 104 molecules per nanocapsule and Dox loading were 1.51 × 104 and 7.64 × 104 molecules per
nanocapsule, respectively. RGD-functionalized nanocapsules had an improved uptake capacity by
U87MG cells. Pareto chart showed that the cell viability was mainly affected by the Dox concentration
and the period of treatment in both MCF-7 and U87MG. The influence of RGD-functionalization on
cell viability was a determinant factor exclusively to U87MG.
Keywords: lipid-core nanocapsules; cancer; RGD; Doxorubicin; active drug targeting;
surface-functionalization
1. Introduction
Cancer is a major public health problem worldwide. In the past decades, several nanoparticle-
based drug delivery systems have obtained a great attention as promising approaches for tumor
treatments [1–4]. The use of nanotechnology in drug delivery systems opened new opportunities to
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overcome limitations in therapeutics, such as low efficacy and high systemic toxicity of many drugs in
clinical practice for cancer treatments [5].
Doxorubicin (Dox), an anthracycline antibiotic and anticancer drug, is used as a cytostatic agent
in cancer chemotherapy [6]. Unfortunately, Dox clinical use is limited by dose-related cardiomyopathy,
which becomes more prevalent with increasing cumulative doses [7]. Therefore, poor penetration
of antitumor drugs into the extravascular tumor tissue is often a major factor limiting the efficacy of
treatments [8,9].
To demonstrate efficacy, most of the anti-cancer drugs have to reach and internalize the cancer cells
in a correct and appropriate concentration for an effective activity level [10]. Moreover, ligand-mediated
chemotherapeutic drug targeting has emerged as a novel paradigm in targeting cancer contributing
to selectively destroy cancer cells and reduce adverse effects to normal cells. Antecedently, various
biocompatible nanoparticles with different structures and compositions have been identified as promising
devices for drug targeting in the treatment of tumoral cells [2,11,12]. Surface functionalization of
nanoparticles has traditionally been achieved using targeting groups, such as peptides or antibodies
for specificity [10]. Conjugation of peptides at the surface of nanoparticles are in general developed using
two approaches: by covalent binding of the protein to the surface of nanoparticle or by noncovalent
interactions between the particle and protein [13].
Angiogenesis, the development of new blood vessels, plays a critical role in controlling tumor
growth and metastasis. Several cell surface-proteins, over-expressed by tumor endothelial cells,
contribute to cell invasion and angiogenesis. Among them, the role ofαvβ3 integrin in angiogenesis and
tumor cell proliferation is well documented [14,15]. The αvβ3 integrin is highly expressed (in different
levels) in new blood vessels of tumors, as well as in cells of different solid tumors, such as glioblastomas,
melanomas, ovarian cancer, breast cancer and prostate cancers [3,16–18]. The recognition of the widely
expressed peptide sequence arginylglycylaspartic acid (RGD) favor its use as active targeting ligand of
drugs [9,19–21]. Polymeric nanoparticles functionalized with RGD and containing DOX have been
designed and developed for targeting tumor cells [22–24]. Using the phase inversion method and
a conjugation with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene
glycol)-2000]. Hirsjärvi and co-workers [25] developed lipid nanocapsules grafted with a RGD
cyclic-peptide (cRGD). Those nanocapsules are prepared with no hydrophobic polymer wall having
their surface decorated with cRGD by a covalent bond with a lipophilic constituent material
of the nanocapsules. The nanocapsules bound efficiently to cell integrins (U87MG cells) with
effective internalization.
In our research group, we developed a kind of polymeric nanocapsules named lipid-core
nanocapsules (LNC), which structure is an organogel as core (sorbitan monostearate and capric-caprylic
triglyceride), a polymer wall (composed of a hydrophobic polyester) and a hydrophilic corona
of polysorbate 80 micelles [26]. The lipid-core nanocapsules (LNC) showed their promising
application in the treatment of cancer based on a variety of studies that we conducted with
different encapsulated drugs carried and deliver to cells, tissues and organs [27–30]. Recently,
we developed a liquid formulation containing Dox-loaded lipid-core nanocapsules (Dox-LNC)
showing its in vitro antiproliferative activity against human breast cancer cell line (MCF-7 cells),
which efficacy is related to the mechanism of cell uptake, mainly endocytosis mediated by caveolin [31].
In parallel, we developed an innovative strategy to decorate the surface of the lipid-core nanocapsules
by coating them with lecithin-chitosan and coordinating ligands at the surface by forming an
organometallic complex using zinc-II or iron-II [32]. The new supramolecular structures were
complexed by a quick and versatile non-covalent bound with different molecules, such as an
antibody fragment anti-LDL(-), scFv-anti-LDL(-) [32,33] and enzymes, such as laronidase [34] as
well as bromelain [35]. Taking into account the above mentioned, we hypothesis that our previous
liquid formulation containing Dox-LNC could be surface functionalized using the chitosan-metal
ion-ligand-complex interfacial reaction to improve the tumor targeting by using RGD as active targeting
ligand. Then, RGD-surface-functionalized-Dox-loaded lipid-core-nanocapsules were developed and
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physico-chemically characterized by diverse techniques and biologically evaluated using two different
tumoral cell cultures (human breast adenocarcinoma cell line, MCF-7; and human glioblastoma
astrocytoma, U87MG), which cell membranes express αvβ3 integrin in different levels.
2. Results
2.1. Surface-Functionalized Metal-Complex Multi-Wall Nanocapsules
The lipid-core nanocapsules were prepared by self-assembling methodology injecting an organic
phase into an aqueous phase following evaporation to remove acetone and concentrate the formulation.
The nanocapsules were, then, coated with chitosan. The chitosan-coated nanocapsule surface was
reacted with zinc acetate and RGD. RGD-MCMN was obtained as macroscopically homogenous
white-opalescent liquid. Photon correlation spectroscopy (PCS) analysis showed hydrodynamic mean
diameter (z-average) of 162 ± 6 nm, polydispersity index (PDI) of 0.11 ± 0.04 and zeta potential of
+13.2 ± 1.9 mV. By NTA, the hydrodynamic mean diameter and particle number density (PND) were
192 ± 10 nm and (6.2 ± 1.1) × 1011 particles mL−1, respectively. Formulation was prepared with an
RGD concentration of 843.64 µmol L−1. After ultrafiltration-centrifugation, we determined the yield
of RGD complexation on the surface of the nanocapsules as 94.3 ± 5.9%. In this way, the interfacial
reaction yielded 7.73 × 104 RGD molecules per nanocapsule.
In order to establish the influence of the RGD functionalization on the cell viability study,
we prepared a formulation functionalized with phenylalanine (Phe), named here Phe-MCMN,
as previously proposed as a control formulation in biological evaluations [33]. The new batch of
this formulation had physico-chemical characteristics such as, z-average diameter of 188 ± 3 nm, PDI
of 0.12 ± 0.02 and zeta potential of + 25 ± 2 mV. Phe-MCMN and RGD-MCMN showed unimodal
distributions of diameters by PCS (Figure 1). It is noteworthy to mention the profiles expressed by
intensity and by volume, in each case, are almost superimposed denoting the narrow size distributions
of nanocapsules.
Figure 1. Diameter distribution profiles by intensity and by volume of particles determined by photon
correlation spectroscopy (PCS) for surface-functionalized metal-complex multi-wall nanocapsules
using phenylalanine or RGD as ligands (Phe-MCMN and RGD-MCMN).
To determine the cytotoxicity of the nanoformulations, we prepared drug-loaded formulations
containing Dox at 0.1 and 0.5 mg·mL−1. Therefore, the Dox-loaded nanoformulations functionalized
with RGD were obtained as macroscopically homogeneous red-orange opalescent liquids. PCS and
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NTA showed nanoscopic populations, with mean diameters lower than 215 nm (Table 1). We also
prepared Dox-loaded formulations functionalized with phenylalanine (Phe-MCMN (Dox100) and
Phe-MCMN (Dox500)) to evaluate the influence of the chemical nature of the ligand on the cell viability.
These nanoformulations were obtained as macroscopically homogeneous red-orange opalescent liquids.
PCS and NTA analysis showed diameter profiles with narrow size distributions with mean diameters
lower than 208 nm (Table 1). All nanoformulations containing Dox showed PDI lower than 0.10, PND
close to 7 × 1011 nanocapsules per mL and zeta potential around +15 mV (Table 1).
Table 1. Physicochemical characterization of formulations containing Doxorubicin by photon
correlation spectroscopy (PCS), nanoparticle tracking analysis (NTA) and electrophoretic light scattering
(ELS) (mean ± SD).
Formulation
PCS NTA ELS
Z-Average
Diameter (nm)
Mean Size
(nm) PDI
PND (×1011
Particles mL−1)
Zeta Potential
(mV)
RGD-MCMN (Dox100) 146 ± 20 128 ± 12 0.09 ± 0.05 6.9 ± 0.6 +13.8 ± 2.3
RGD-MCMN (Dox500) 215 ± 25 135 ± 21 0.09 ± 0.03 6.1 ± 1.0 +16.4 ± 1.5
Phe-MCMN (Dox100) 186 ± 19 110 ± 25 0.08 ± 0.05 6.9 ± 0.3 +17.1 ± 0.7
Phe-MCMN (Dox500) 208 ± 22 132 ± 15 0.09 ± 0.02 6.5 ± 0.7 +16.5 ± 1.4
Drug contents of 92.49 ± 7.17 and 457.55 ± 5.41 µg·mL−1 were experimentally determined for
the Dox-loaded formulations prepared at 100 and 500 µg·mL−1, respectively. After ultrafiltration-
centrifugation, drug encapsulation efficiencies were 91.58 ± 0.70% for RGD-MCMN (Dox100) and
92.61 ± 3.00% for RGD-MCMN (Dox500).
2.2. Cellular Uptake Studies
We prepared fluorescent-labeled nanoformulations by using a blend of PCL with a
PCL-Rhodamine B conjugate. After treating the MCF-7 and U87MG cells with the fluorescent
labeled-nanoformulations, confocal microscopy images showed fluorescence emission for both
Phe-MCMNf and RGD-MCMNf but in higher intensity for the latter in both cell cultures suggesting a
higher RGD-MCMNf cellular uptake (Figure 2).
Figure 2. MCF-7 (a) and U87MG (b) cells were seeded at densities of 6.0 × 103 and 20.0 × 103 cells
per well, respectively. Confocal microscopy analysis of cellular uptake after 24 h of treatment using
the fluorescent-labeled nanoformulations (Phe-MCMNf and RGD-MCMNf) at 5.15 × 10−3 µmol·L−1
of well). Photomicrographies were obtained at 20× magnification with an Olympus IX71 fluorescent
microscope (Olympus Corporation, Tokyo, Japan) (bar = 100 µm).
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On the other hand, by flow cytometry, despite the efficient uptake of Phe-MCMN and
RGD-MCMN by human breast cancer cells MCF-7 cells, no statistical difference between the
formulations was observed, whatever the nanocapsule concentration applied (Figure 3a). Therefore,
we selected the lowest concentration of nanocapsules to treat the U87MG cells and to compare the
cellular uptake of these formulations (Figure 3b). In this case, RGD-MCMN demonstrated an improved
uptake capacity for U87MG cells, while Phe-MCMN presented higher uptake for MCF-7 cells.
Figure 3. (a) Flow cytometry uptake profiles of Phe-MCMNf or RGD-MCMNf by MCF-7 cells treated
for 24 h with 1.03 × 10−4, 2.06 × 10−4, 3.09 × 10−3, 3.72 × 10−3 and 5.15 × 10−3 µmol of nanocapsules
per liter of well; and (b) uptake of RGD-MCMNf and Phe-MCMNf by MCF-7 and U87MG cells treated
for 24 h with 1.03× 10−4 µmol of particles per liter of well; control groups did not receive any treatment.
Notes: Data are expressed as mean ± standard error. * Indicates significant differences from control;
# indicates significant differences compared to the respective concentrations in (a,b); *# indicates
significant differences between cell lines. Differences were considered significant at p < 0.05.
2.3. Cell Viability Studies
The MTT assay was used to evaluate whether the drug-unloaded nanocapsule formulations
(Phe-MCMN and RGD-MCMN) affect the cell viability of MCF-7 and U87MG cells after 24 h of
treatment. To MCF-7 culture, no significant difference was observed in cell viability after treatments
with increasing concentrations of Phe-MCMN and RGD-MCMN compared to the control group
(Figure 4). While, to U87MG culture, all concentrations of RGD-MCMN applied showed significant
decrease in cell viability compared to the control but only the highest concentrations of Phe-MCMN
showed significant difference (Figure 4).
To determine the cytotoxicity of Dox-loaded nanoformulations, we carried out the MTT assay
applying the formulations at concentrations of 1.03 × 10−4 and 2.06 × 10−4 µmol of nanocapsules
per liter of well incubating them for 24 and 72 h. Dox-loaded nanocapsules were compared to Dox
solution and the cell viability of the treated groups were calculated in relation to the control group
(without treatment), which represents 100% of cell viability. During MTT assay, treated groups did
not show significant alterations in the proliferation of the cell line when compared with the untreated
group (control). After 24 and 72 h of treatment, all Dox treatments led to a significant decrease in cell
viability in comparison with their respective control groups (p ≤ 0.05).
MCF-7 cells were treated with drug concentration from 1.7 to 17 µmol of Dox per liter of well
using two different concentrations of nanocapsules: 1.03 × 10−4 or 2.06 × 10−4 µmol of nanocapsules
per liter of well. In the treatments with Doxorubicin concentration of 1.7 and 3.4 µmol·L−1, we used
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RGD-MCMN (Dox100), Phe-MCMN (Dox100) and Dox100, while for Doxorubicin concentration of
8.5 and 17 µmol·L−1 we used RGD-MCMN (Dox500), Phe-MCMN (Dox500) and Dox500. Taking into
account the encapsulation efficiencies, the number Dox molecules per nanocapsule is about 1.51 × 104
or 7.64 × 104, respectively, for the formulations prepared using 100 and 500 µg of Dox per milliliter.
Figure 4. (a) Effect of Phe-MCMN and RGD-MCMN on the cell viability of human breast cancer cells
(MCF-7 cell line) and (b) glioblastoma cells (U87MG cell line) using MTT assay. Cells were treated for
24 h with different nanocapsule concentrations (1.03 × 10−4, 2.06 × 10−4, 3.09 × 10−3, 3.72 × 10−3 and
5.15 × 10−3 µmol of particles per liter of well). Control group did not receive any treatment (100% cell
viability). Notes: data are expressed as mean± standard error. * Indicates significant differences compared
to the control; # indicates significant differences compared to the respective concentrations; *# indicates
significant differences between cell lines. Differences were considered significant at p < 0.05.
After 24 h of incubation, MTT assay (Figure 5) showed a cell viability from 65.67 ± 4.73%
to 43.59 ± 0.81% for RGD-MCMN (Dox), 88.19 ± 2.70% to 43.72 ± 2.26% Phe-MCMN (Dox) and
52.93 ± 4.41% to 42.35 ± 2.40% for Dox. The treatments with 1.7 and 3.4 µmol of Doxorubicin per
liter of Phe-MCMN (Dox) formulation did not present significant difference (p > 0.05) compared to
the control (100% of viability). Furthermore, no statistical difference was determined comparing
the formulations containing the highest concentration of Dox (p > 0.05). Nevertheless, regarding
treatments with 1.7 and 3.4 µmol of Dox per liter of well using RGD-MCMN (Dox), a greater decrease
in the viability of MCF-7 cells was observed compared to Phe-MCMN (Dox) (p < 0.05). MTT assay
carried out with U87MG cells, after 24 h of treatment with similar Dox concentrations using the same
formulations showed a cell viability from 51.45 ± 0.96% to 35.24 ± 0.51% for RGD-MCMN (Dox), from
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54.43 ± 3.26% to 48.48 ± 0.94% for Phe-MCMN (Dox) and from 86.87 ± 5.24% to 61.10 ± 1.70% for
Dox. The treatments using 1.7 and 3.4 µmol of Dox per liter of well did not show significant difference
(p > 0.05) compared to the control (100% of viability). No statistical difference was determined
comparing RGD-MCMN (Dox) and Phe-MCMN (Dox) using 1.7 and 3.4 µmol of Dox per liter of
well (p > 0.05). In addition, nanocapsule formulations showed higher cytotoxicity than Dox in all
concentrations of treatment (p < 0.05) and RGD-MCMN (Dox) showed the highest decrease of viability
among the formulations.
Figure 5. Cell viability by MTT assay after 24 h of treatment on (a) human breast cancer cells (MCF-7
cell line) and (b) glioblastoma cells (U87MG cell line) using nanocapsule concentrations at 1.03 × 10−4
and 2.06 × 10−4 µmol per liter of well and Doxorubicin concentrations at 1.7, 3.4, 8.5 and 17.0 µmol
per liter of well. Control group did not receive any treatment (100% cell viability).Notes: Data are
expressed as mean ± standard error. * indicates significant differences from control; # indicates
significant differences compared to the respective concentrations; *# indicates significant differences
between cell lines. Differences were considered significant at p < 0.05.
After 72 h of incubation, MTT assay (Figure 6) in MCF-7 showed cell viability from 57.17 ± 4.20%
to 21.15 ± 5.00% for RGD-MCMN (Dox), from 57.04 ± 0.87% to 20.93 ± 5.00% for Phe-MCMN (Dox)
and from 46.45 ± 1.77% to 25.26 ± 2.16% for Dox. All treatments presented significant difference
(p < 0.05) compared to the control. Only RGD-MCMN (Dox) demonstrated significant difference
(p < 0.05) compared to other treatments in similar concentration. After 72 h, MTT assay carried out
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with U87MG cells, showed cell viability from 26.77 ± 3.21% to 3.21 ± 4.00% for RGD-MCMN (Dox),
from 33.62± 4.17% to 20.93± 5.00% for Phe-MCMN (Dox) and from 65.89± 6.56% to 27.26± 2.16% for
Dox. All treatments presented significant difference (p < 0.05) compared to the control. Dox presented
significant difference (p < 0.05) compared to the treatments using 1.7 and 3.4 µmol of Dox per liter
of well. RGD-MCMN (Dox) showed the highest decrease in cell viability compared to the other
treatments using 17 µmol of Dox per liter of well (p < 0.05).
To analyze the results considering all parameters (factors) varying among the groups of treatments,
a Pareto chart was constructed (Figure 7). The factors that most influenced the decrease in cell viability
or the interaction of factors were evaluated. The vertical line indicates the minimum value of effect
for the significant cell death; and the greater the effect, the greater the significance. In Pareto chart
for MCF-7 cells, Dox concentration and period of treatment were the factors that most influenced the
results. While, for U87MG cells, the period of treatment, the surface-functionalization and the Dox
concentration were the factors that most influenced the results of cell viability.
Figure 6. Cell viability by MTT assay after 72 h of treatment on (a) human breast cancer cells (MCF-7 cell
line) and (b) glioblastoma cells (U87MG cell line) using nanocapsule concentrations at 1.03 × 10−4 and
2.06 × 10−4 µmol per liter of well and Doxorubicin concentrations at 1.7, 3.4, 8.5 and 17 µmol·per liter
of well. Control group did not receive any treatment (100% cell viability). Notes: data are expressed
as mean ± standard error. * Indicates significant differences from control; # indicates significant
differences compared to the respective concentrations; *# indicates significant differences between cell
lines. Differences were considered significant at p < 0.05.
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Figure 7. Standardized effects of A = functionalization, B = Dox concentration, C = nanocapsule
concentration, D = period of incubation and their interaction effects on the cell death ((a) MCF-7 cells;
and (b) U87MG cells).
3. Discussion
In spite of much ongoing research about cancer, the treatment of tumors still proves
difficult. Therefore, various nanoparticles based drug delivery systems have been studied [2,27,29].
The targeting of RGD-modified nanoparticles to tumor vasculature is a promising strategy for
tumor-targeting treatment, because some tumor cells within solid tumors would overexpress ανβ3
integrin, which can specifically recognize the peptide RGD [20,23,36–38]. Buckley and co-workers [39]
described that RGD-containing peptides enter cells and directly induce autoprocessing and enzymatic
activity of procaspase-3, a pro-apoptotic protein.
We developed the RGD-surface-functionalized metal-complex multi-wall nanocapsules by
adapting the methodology we previously described [32] to obtain scFv-anti-LDL(-)-surface-
functionalized multi-wall-nanocapsules. Different formulations were prepared to compare the
effect of the encapsulated drug (Dox) and the ligand (RGD) on the cell viability of MCF-7 and
U87MG. To evaluate the influence of the integrin recognition on the cell viability assays, we also
prepared formulations without Dox but functionalized with Phe (Phe-MCMN) or RGD (RGD-MCMN).
RGD-MCMN was more efficient to inhibit the growth of U87MG cells (human glioblastoma cells
expressing high levels of integrin ανβ3) than similar concentrations of Phe-MCMN. In parallel, none
of those formulations was cytotoxic to MCF-7 cells in similar experimental conditions.
Integrins are heterodimeric membrane glycoproteins composed of non-covalently associated α
and β subunits. The αvβ3 integrin is highly expressed in U87MG cells, which express approximately
105 αvβ3 receptors per cell [40]. However, according to Zhang et al. [41] the quantification of αvβ3
integrin expression in cells or tissues by immunoblotting is technically challenging because both
anti-αv and anti-β3 antibodies are thus needed to confirm the presence of αvβ3 integrin. Liu and
co-workers [38] could not detect β3 integrin in MCF-7 cells by either RT-PCR or western blots.
Additionally, the absence of β3 integrin they showed the inability of MCF7 cells to form αvβ3
heterodimers. Besides, αvβ3 integrin is not expressed on mature vessels or on non-neoplastic
epithelium [41].
The supramolecular structure of the multi-wall nanocapsules is based on secondary bonds
among the lipids and the lipids and PCL, as well as on the electrostatic interactions between the
ammonium groups of chitosan and the negatively charge groups present in Lipoid S75 (lecithin).
The addition of zinc acetate solution leads to the chitosan-metal complex formation. This complex is
highly reactive [32,42] and, then, capable of reacting with different molecular compounds, such as
RGD. The formulations developed in this study presented unimodal and nanometric particle sizes,
which characteristics are consistent with the diameters usually observed for polymeric nanocapsules
dispersed in water prepared by solvent displacement method. A narrow particle distribution was
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observed for the formulations, indicated by the low polydispersity. The zeta potential values were
positive as previously described for chitosan-coated nanocapsules [32].
To the Dox-loaded nanocapsules, the encapsulation efficiency (EE%) was higher than 90% for
both drug concentrations (100 or 500 µg·mL−1), demonstrating the high capacity of Dox loading
on these nanocapsules. The high EE% in the present study is attributed primarily to the neutral
drug form interacting with the lipid-core of the nanocapsules and also to probable electrostatic
interactions between amine groups of Dox molecules and the oxygenated groups of Lipoid S75
(lecithin). Similarly, as previously described, Dox can be associated with the nanoparticles by
electrostatic interactions [43–47]. Considering the organometallic complex at the nanocapsule surface,
the binding of RGD-peptide on the nanocapsule was 94.3± 5.9%. These results demonstrated adequate
encapsulation efficiency and surface functionalization to conduct the in vitro biological evaluations.
The cell viability study after 24 h of treatment with blank formulations (RGD-MCMN and Phe-MCMN)
was conducted to evaluate their toxicity to the MCF-7 and U87MG cells. Besides that, our results also
showed potent cytotoxicity of formulations containing Dox when functionalized with RGD. After 72 h
of treatment, these formulations were able to eliminate almost 100% of the human glioblastoma
cells. Moreover, they also presented high cytotoxicity effect to MCF-7 cells. Previously, Yu and
co-workers [40] demonstrated that Dox-loaded nanoparticles functionalized with RGD showed much
higher effect to U87MG cells, than to MCF-7 cells, which presents low expression of this integrin.
Recently, magnetic RGD cycle-peptide-functionalized nanoparticles containing Dox resulted in the
low efficiency of targeted drug delivery in MCF7 cells and were able to dramatically increase the drug
efficacy to U87MG cells probably due to the receptor-mediated endocytosis. Moreover, the applied
magnetic fields further affected the cytotoxicity of magnetic nanoparticles because the concentrations
of drug nanocarriers around cancer cells can be manipulated by remote control using small magnets for
these cells [48]. In addition, Dox-encapsulated nanoparticles formed by poly(RGD-co-β-amino ester)
and Dox-polymeric nanoparticles functionalized with RGD had higher cytotoxicity than nanoparticles
prepared without RGD in U87MG cells [24]. Besides these, in recent years, other authors have
described the improvement in transport of Dox into tumor cells with targeting of RGD-nanoparticles
using different materials and methods of preparation [37,49–53].
Different from the nanoparticles cited in these studies, we used surface coordination ligands for
non-covalent binding to RGD. In general, the nanoparticle surface functionalization with ligands, such
as peptides is carried out primarily by conjugation methods. Conjugation of ligands can be random
or site specific and random conjugation can cause a lack of the ligand specificity. Thus, the ability to
specifically bind to its target receptor might be decreased. Therefore, a strategy of surface coordination
ligands for non-covalent binding can ensure full ligands activity [32].
Phe-MCMN (Dox) showed promising results regarding the cytotoxicity in MCF-7 and U87MG
cells. Those findings are likely explained by the aromatic residue of Phe as lateral chain, which
can cause an increase in rupture capacity of the endosomal membrane as previously reported by
Plank [54]. Furthermore, hydrophobic microparticles and dendrimers containing Phe have led to the
destabilization or rupture of membrane in dendritic cells and macrophages [55,56]. Other studies
also describe higher activity for membrane rupture by polymers containing Phe and its use to deliver
intracellularly drugs [57,58]. In parallel, Ho and co-workers [59] developed pH-responsive biomimetic
pseudo-peptides synthesized by grafting L-phenylalanine onto the pendant carboxylic acids of a
polyamide, poly(L-lysine isophthalamide) polymers containing Phe and showed effective penetration
into tumor models (HeLa—cervical cancer cells), leading to improvements in therapeutic delivery for
extracellular and intracellular tumors.
Pareto chart allowed confirming the importance of surface functionalization with RGD to decrease
U87MG cell viability. In addition to this effect, Dox concentration and period of treatment were also
significant to decrease cell viability for both tumor cells. Our hypothesis was validated. The significant
effect of functionalization to inhibit the growth of U87MG cells is a consequence of the RGD targeting
effect on these cells, which have specific integrin to bind RGD [14,24,48,50].
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The fluorescence from nanocapsules was observed to U87MG and MCF-7 cells, showing the
uptake of RGD-MCMNf and Phe-MCMNf by both tumor cells. Therefore, the cellular uptake
study showed that the increase in the nanocapsule concentration enhanced the fluorescence detected
indicating a correlation to the cellular uptake. Besides, the similarity of Phe-MCMN and RGD-MCMN
to MCF-7 cells viability, as well as the highest cellular uptake of RGD-MCMNf by U87MG
cells corroborate to the Pareto chart analysis, which demonstrated the importance of the RGD
functionalization to decrease the viability of U87MG cells. Wang and co-workers [22] carried out
cellular uptake studies with B16F10, DU145, MD-MB231 and MCF-7 cells, which have different
expression levels of αvβ3 as well as RGD-nanoparticles and showed higher cellular uptake to B16F10
and MD-MB231 cells, with greater expression of αvβ3 integrin on the membrane.
We previously investigated the toxicity of drug-unloaded LNC formulation prepared with PCL
using in vivo models after oral and intraperitoneal administrations, respectively, to Caenorhabditis
elegans [60] and Wistars rats [61]. The results showed that LNC is a safe formulation. Besides that,
phenylalanine-surface functionalized nanocapsules (Phe-MCMN), which organometallic complex was
also prepared with Zn2+, caused no significant changes in the cell death (apoptosis + necrosis) in both
the RAW 264.7 macrophages and HUVEC cell lines [33]. Even though RGD-surface-functionalized
metal-complex multi-wall nanocapsules can be considered a supramolecular derivative of LNC and
Phe-MCMN, further studies are necessary to access their safety.
4. Materials and Methods
4.1. Materials
Doxorubicin hydrochloride (98–102%), Span® 60 (sorbitan monostearate), Poly(ε-caprolactone)
(α,ω-dihydroxy functional polymer, Mn 10 kg·mol−1, Mw 14 kg·mol−1), chitosan low molar
weight (Mw 50–190 kg·mol−1, 75–85% deacetylated polymer), zinc acetate (catalog number 383317),
QuantiPro™ BCA Assay Kit, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MMT)
and arginylglycylaspartic acid (RGD) were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Caprylic/capric triglyceride and Tween® 80 (polysorbate 80) were delivered by Delaware (Porto Alegre,
Brazil). Lipoid® S75 (soybean lecithin) was obtained from Lipoid (Ludwigshafen am Rhein, Germany).
Solvents used were of analytical or pharmaceutical grades. For cell culture studies, the human breast
cancer cell line (MCF-7) and the human glioblastoma cell line (U87 MG) were obtained from the
American Type Culture Collection (Rockville, MD, USA; ATCC HTB-22 and HTB-14). Dulbecco’s
modified Eagle’s medium (DMEM low) and fetal bovine serum (FBS) were purchased from Invitrogen
(Waltham, MA, USA).
4.2. Preparation of Surface-Functionalized Metal-Complex Multi-Wall Nanocapsules (MCMN)
4.2.1. Neutralization of Doxorubicin Hydrochloride
Dox (base) was obtained as previously reported [62]. Briefly, Dox·HCl was dissolved in MilliQ®
water at 1 mg·mL−1. The orange-red solution was transferred to a separating funnel, added of
trimethylamine (turning to violet) and extracted with chloroform (orange). The process was repeated
until the aqueous phase was colorless. The organic phases were combined, dried under anhydrous
sodium sulfate, filtered and evaporated under reduced pressure (Büchi, Flawil, Switzerland). Batches of
0.001 or 0.005 g were produced. The Dox (base) was dissolved in acetone and the solution was used to
produce the formulations as described below.
4.2.2. Preparation of Lecithin-Polysorbate 80-Coated Lipid-Core Nanocapsules (LNC)
Poly(ε-caprolactone) (0.100 g), Span® 60 (0.040 g) and caprylic/capric triglyceride (0.120 g) were
dissolved in acetone (25 mL) containing Dox (base) at 40 ◦C. Then, a solution of Lipoid S75® (0.090 g)
in ethanol (7 mL) was added into the organic phase. This organic solution was injected into an
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aqueous phase (53 mL) containing Tween® 80 (0.080 g) under magnetic stirring at 40 ◦C. After 10 min,
the organic solvents were evaporated and the formulation concentrated under reduced pressure at
40 ◦C using a rotary evaporator (Büchi, Flawil, Switzerland). A formulation containing no drug was
also prepared as described above using acetone without Dox.
4.2.3. Chitosan Coating
Chitosan coating was performed as described previously [32,33]. A 7 mg·mL−1 chitosan solution was
prepared by dispersing chitosan in 1% acetic acid aqueous solution (MilliQ® water). The solution was
filtered (0.45 µm, Millipore, Burlington, MA, USA) and dropwise added (1 mL) into lecithin-polysorbate
80-coated lipid-core nanocapsule aqueous dispersion (9 mL) under magnetic stirring (500 rpm).
The reaction was carried out under magnetic stirring for 3 h at room temperature (20 ◦C).
4.2.4. Surface Functionalization
The surface functionalization was carried out by forming an organometalic complex adapting
the methodology previously described for nanocapsules decorated with an antibody fragment [32].
A 1 mg·mL−1 zinc acetate aqueous solution (MilliQ® water) was prepared at 25 ◦C. Then, 250 µL of
this solution was added into 9.75 mL of chitosan-lecithin-polysorbate 80-coated lipid-core nanocapsule
aqueous dispersion under magnetic stirring (500 rpm). After 1 min, 351.21 µL of this complexed
nanocapsule aqueous dispersion was added of 648.79 µL of a 450 µg·mL−1 RGD aqueous solution
under magnetic stirring (500 rpm) at room temperature (20 ◦C).
In parallel, to obtain phenylalanine-functionalized nanocapsules, 250 µL of the zinc acetate
solution was added into 9.75 mL of chitosan-lecithin-polysorbate 80-coated lipid-core nanocapsule
aqueous dispersion under magnetic stirring (500 rpm). After 1 min, the reaction medium (10 mL) was
added of 250 µL of 7.6 mg·mL−1 phenylalanine aqueous solution under magnetic stirring (500 rpm),
using a ligand/metal molar proportion of 3:1.
Formulations prepared without Dox were named RGD-MCMN and Phe-MCMN,
while formulations containing Dox at 100 and 500 µg·mL−1 were respectively named RGD-MCMN
(Dox100), RGD-MCMN (Dox500), Phe-MCMN (Dox100) and Phe-MCMN (Dox500).
For the cell uptake study, fluorescent-labeled formulations were prepared using a PCL derivative
as previously described by Poletto and co-workers [63]. The conjugate was obtained by the
esterification of Poly(ε-caprolactone) (PCL) with rhodamine B (PCL-RhoB) using an acid activating
agent (carbodiimide). In this case, a blend of PCL (0.090 g) and PCL-RhoB (0.010 g) was used to
constitute the polyester wall of the nanocapsules using the methodology described above.
4.3. Photon Correlation Spectroscopy and Laser Doppler Micro-Electrophoresis
Photon correlation spectroscopy (PCS) and laser Doppler micro-electrophoresis were carried out
in a Zetasizer Nanoseries® ZS instrument (Malvern, UK). Mean diameter by intensity (z-average)
was determined by PCS using the Cumulants method. The samples (20 µL) were diluted to 10 mL in
purified water (1:500 v/v) and zeta potential was determined by laser Doppler micro-electrophoresis
by Zetasizer Nanoseries® ZS instrument (Malvern, UK), after dilution of the samples in 10 mmol·L−1
NaCl aqueous solution (1:500 v/v).
4.4. Nanoparticle Tracking Analysis
The particle number density (particles mL−1), hydrodynamic diameter and median diameter
by number of particles were determined by nanoparticle tracking analysis (NTA) in a NanoSight
LM10 instrument (NanoSight Ltd., Salisbury, UK) using the provided analytical software NTA 2.0
(NanoSight Ltd., Salisbury, UK). This analysis allowed the observation of the Brownian motion
recording the light scattered by the individual nanoparticles. Samples were diluted 5000× in ultrapure
water (Milli-Q®; Merck KGaA, Darmstadt, Germany) and injected into the sample chamber. Each video
clip was captured over 60 s.
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4.5. Drug Content and Encapsulation Efficiency
Dox was quantified by liquid chromatography (HPLC), adapting a method previously
described [64]. The system was a HPLC Shimadzu equipped with a CBM-20A controller, a SPD-M20AV
detector, a degasser DGU-20A5, a LC-20AT pump and a SIL-20A auto-sampler (Kyoto, Japan). A guard
column Cartridges C18 (4.0 × 3.0 mm, Phenomenex, Torrance, CA, USA) and a column RP-18 (150 mm
× 4.6 mm × 5 µm ODS2 Waters Spherisorb®, Waters Corporation, Milford, MA, USA) were used as
stationary phase and a solution of 0.1% trifluoroacetic acid and acetonitrile (50:50, v/v) at apparent pH
2.65, as the mobile phase. The flow rate was 1.0 mL·min−1, using an injection volume of 50 µL and
detection at 254 nm.
To determine the experimental drug content (total concentration of Dox in the formulation),
Dox was extracted from the formulations (0.5 mL) using acetonitrile (5 mL). The mixtures were
stirred for 5 min and filtered (0.45 µm; Merck KGaA) for injection (HPLC). To determine the
encapsulation efficiency (EE%), the non-encapsulated fraction of DOX was also determined.
The ultrafiltration-centrifugation technique was carried out using 10 kDa cutoff units (Merck KGaA)
and centrifugation at 1844× g for 5 min (Sigma® 1-14; SIGMA Laborzentrifugen GmbH, Osterode am
Harz, Germany). The non-encapsulated fraction of Dox (fraction of drug dissolved in the continuous
phase) was determined by HPLC in the ultrafiltrate without dilution. Then, EE% was calculated using
Equation (1).
EE% = (Ct − Cnon-encap)/Ct × 100 (1)
where Ct is the experimental drug content and Cnon-encap is the fraction of Dox dissolved in the
water phase.
4.6. Yield of RGD Complexation on the Nanocapsule Surface
The yield of RGD complexation on the nanocapsule surface was determined by an indirect
method. The non-bound fraction of RGD in the formulations was quantified by a colorimetric
method (QuantiPro™ BCA Assay Kit, Sigma-Aldrich, St. Louis, MO, USA). According to the
manufacturer’s instructions, a calibration curve was prepared using dilutions of bovine serum albumin
(BSA) from 3 to 27 µg·mL−1. The reaction product has absorbance at 562 nm recorded on a plate
reader (Spectramax, Molecular Devices, Sunnyvale, CA, USA). To isolate the non-bound fraction
of RGD, the RGD containing samples were placed in ultrafiltration-centrifugation units (30 kDa;
Merck KGaA) centrifuged at 1840× g Relative Centrifugal Force (RCF) during 5 min (Sigma® 1-14;
SIGMA Laborzentrifugen GmbH, Germany). The ultrafiltrate was assay using the colorimetric method
and the RGD concentration determined using the calibration curve. The yield of RGD complexation
on the nanocapsule surface (Yield%) was determined using Equation (2).
Yield% = (RGDtotal − RGDnon-bound)/RGDtotal × 100 (2)
where RGDtotal is the RGD concentration in the formulation and RGDnon-bound is the RGD concentration
dissolved in the ultrafiltrate.
4.7. Cell Culture Assays
Cell cultures were grown in DMEM (Dulbecco’s Modified Eagle) supplemented with 10% of fetal
bovine serum (FBS), 0.1% amphotericin, 1% penicillin/streptomycin (Invitrogen, Waltham, MA, USA)
in an atmosphere of 5% CO2/95% air at 37 ◦C. Fresh medium was replaced every other day.
4.8. Confocal Microscopy Analysis
For confocal microscopy analysis cellular uptake, MCF-7 and U87MG cells were seeded at
densities of 6.0× 103 and 20.0× 103 cells per well, respectively, in 24-well plates. After reaching 60% to
70% of confluency, cells were treated with the fluorescent-labeled RGD-MCMNf or fluorescent-labeled
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Phe-MCMNf using 5.15 × 10−3 µmol of particles per liter of well. The volume per well was completed
to 500 µL with DMEM. After incubation for 24 h at 37 ◦C, formulations were removed and cells were
washed with PBS (0.5 mL). After the second addition of PBS (0.5 mL), photomicrographies were
obtained at 20× magnification with an Olympus IX71 fluorescent microscope (Olympus Corporation,
Tokyo, Japan) equipped with the CellSens Standard software (Olympus Corporation, Tokyo, Japan).
4.9. Quantitative Cellular Uptake Studies
Quantitative cellular uptake of fluorescent-labeled RGD-MCMN was evaluated by flow cytometry.
MCF-7 and U87MG cells were seeded at densities of 6.0 × 103 and 20.0 × 103 cells per well,
respectively, in 24-well plates. After reaching 60% to 70% of confluency, cells were treated with
the fluorescent-labeled RGD-MCMNf or fluorescent-labeled Phe-MCMNf using the concentrations of
nanocapsules ranged from 1.03 × 10−4 to 5.15 × 10−3 µmol of particles per liter of well. The volume
per well was completed to 500 µL with DMEM. After incubation for 24 h at 37 ◦C, formulations
were removed and cells were gently washed with PBS buffer (3 times), detached with trypsin-EDTA,
harvested and analyzed in a flow cytometer BD FACSVerse System (BD, Franklin Lakes, NJ, USA)
equipped with a PE filter in order to determine fluorescence intensity emitted by the fluorescent-labeled
RGD-MCMN or fluorescent-labeled Phe-MCMN.
4.10. Cell Viability Studies
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to estimate
MCF-7 and U87MG cell viabilities. Cells were seeded 1500 cells per well for MCF-7 and 5000 cells per well
for U87MG into 96-well plates. After 48 h, the medium (DMEM) was removed, the adherent cells were
treated with each formulation and the volume completed to 100 µL with DMEM. The concentrations of
nanocapsules in the treatments ranged from 1.03× 10−4 to 5.15× 10−3 µmol of particles per liter of well.
The micromolar concentrations of nanocapsules were calculated using the Avogadro number (6.023× 1023)
considering the particle number density (PND) determined as described above using NTA. The cells were
incubated for 24 and 72 h. After incubation, the medium was removed and each well was washed with
phosphate-buffered saline to the addition of 0.5 mg·mL−1 MTT solution. The cells were incubated at 37 ◦C
for 3 h. The MTT solution was removed and DMSO (100 µL) was added to dissolve the formazan crystals.
Thus, the absorbance was measured at 560 nm and 630 nm on a microplate reader (Spectramax M2e
and v 5.4.1, SoftMax Pro Software Interface; Molecular Devices, Sunnyvale, CA, USA). The results were
converted to cell viability, expressed as the percentage of cell viability against the control group, which did
not receive any treatment (100% of cell viability).
4.11. Statistical Analysis
All data are expressed as mean values ± standard deviation calculated from at least
three independent experiments. Statistical analyses were performed using GraphPad Prism 5.0
(GraphPad Software Inc., La Jolla, CA, USA). The level of significance was set to p < 0.05. For the
cell viability results, the software MINITAB version 16.0 (Minitab Inc., State College, PA, USA) was
used to plot the Pareto chart. A graphical display of the effect by factor was given in a Pareto chart,
which analyzes the magnitude and the importance of each variable effect. The length of the bars
in the chart is proportional to the effect. A factor was considered as “statistically significant” if its
standardized effect exceeded a threshold. A line in the Pareto chart indicated the threshold for a test at
the p-value of 0.05.
5. Conclusions
RGD surface modified LNC were successfully developed. Therefore, different Dox concentrations
were nanoencapsulated into these nanocapsules. The cellular uptake of RGD-MCMN was significantly
enhanced to the integrin-overexpressed cell lines (U87MG) compared to the integrin-deficient
cell lines (MCF-7). Moreover, Pareto chart showed that the cell viability was mainly affected
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by Dox concentration and period of treatment in both MCF-7 and U87MG. The influence of
RGD-functionalization on cell viability was a determinant factor exclusively to U87MG. We believe
that this study provides a facile strategy towards the development of active-targeting drug-loaded
nanocarriers for tumor therapy via integrin mediation. In this way, in vivo pre-clinical trials can
be performed to evaluate the innovative formulations as a new chemotherapeutic strategy for drug
delivery to tumor cells without damaging normal cells using αvβ3 integrin targeted antiangiogenic
strategies for cancer treatment by intravenous administration.
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